Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin

Nature Structural and Molecular Biology

Volumn 11, Issue 9, 2004, Pages 857-862

  Li, Wei ^a   Johnson, Daniel J D ^a   Esmon, Charles T ^b   Huntington, James A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN DERIVATIVE; SERINE PROTEINASE INHIBITOR; SR 123781; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD FLOW; CRYSTAL STRUCTURE; ENZYME INHIBITOR COMPLEX; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN FAMILY; THROMBOCYTE AGGREGATION INHIBITION;

ANTITHROMBINS; BINDING SITES; FIBRINOLYTIC AGENTS; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; MODELS, MOLECULAR; MUTAGENESIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; SODIUM; THROMBIN;

EID: 4344590703     PISSN: 15459993     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsmb811     Document Type: Article

References (42)

1. Stubbs, M.T. & Bode, W. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69, 1-58 (1993).
2. Stubbs, M.T. & Bode, W. The clot thickens: clues provided by thrombin structure. Trends Biochem. Sci. 20, 23-28 (1995).
3. Huntington, J.A. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J. Thromb. Haemost. 1, 1535-1549 (2003).
4. Hirsh, J. Blood tests for the diagnosis of venous and arterial thrombosis. Blood 57, 1-8 (1981).
5. Kojima, T. Targeted gene disruption of natural anticoagulant proteins in mice. Int. J. Hematol. 76 (suppl. 2), 36-39 (2002).
6. Mulloy, B. & Linhardt, R.J. Order out of complexity-protein structures that interact with heparin. Curr. Opin. Struct. Biol. 11, 623-628 (2001).
7. Lindahl, U., Thunberg, L., Backstrom, G. & Riesenfeld, J. The antithrombin-binding sequence of heparin. Biochem. Soc. Trans. 9, 499-451 (1981).
8. Casu, B. et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem. J. 197, 599-609 (1981).
9. Rosenberg, R.D. Heparin, antithrombin, and abnormal clotting. Annu. Rev. Med. 29, 367-378 (1978).
10. Olson, S.J. & Chuang, Y.J. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc. Med. 12, 331-338 (2002).
11. Olson, S.T. & Bjork, I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J. Biol. Chem. 266, 6353-6364 (1991).
12. Olson, S.T. Quantitative characterization of the thrombin-heparin interaction. J. Biol. Chem. 266, 6342-6352 (1999).
13. Fareed, J., Hoppensteadt, D.A. & Bick, R.L. An update on heparins at the beginning of the new millennium. Semin. Thromb. Hemost. 26 (suppl. 1), 5-21 (2000).
14. Bray, B., Lane, D.A., Freyssinet, J.M., Pejler, G. & Lindahl, U. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem. J. 262, 225-232 (1989).
15. Kelton, J.G. Heparin-induced thrombocytopenia: an overview. Blood Rev. 16, 77-80 (2002).
16. Petitou, M. et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398, 417-422 (1999).
17. Dementiev, A., Simonovic, M., Volz, K. & Gettins, P.G. Canonical inhibitor-like interactions explain reactivity of α1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J. Biol. Chem. 278, 37881-37887 (2003).
18. Ye, S., et al. The structure of a Michaelis serpin-protease complex. Nat. Struct. Biol. 8, 979-983 (2001).
19. Baglin, T.P., Carrell, R.W., Church, F.C., Esmon, C.T. & Huntington, J.A. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. USA 99, 11079-11084 (2002).
20. Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162 (1967).
21. Jin, L., et al. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. USA 94, 14683-14688 (1997).
22. Chuang, Y.J., Swanson, R., Raja, S.M. & Olson, S.T. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J. Biol. Chem. 276, 14961-14971 (2001).
23. + binding site of thrombin. Biophys. Chem. 63, 185-200 (1997).
24. Sheehan, J.P. & Sadler, J.E. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. USA 91, 5518-5522 (1994).
25. Ye, J., Rezaie, A.R. & Esmon, C.T. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J. Biol. Chem. 269, 17965-17970 (1994).
26. He, X., Ye, J., Esmon, C.T. & Rezaie, A.R. Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry 36, 8969-8976 (1997).
27. Tsiang, M., Jain, A.K., & Gibbs, C.S. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J. Biol. Chem. 272, 12024-12029 (1997).
28. Dang, Q.D., Guinto, E.R. & Di Cera, E. Rational engineering of activity and specificity in a serine protease. Nat. Biotechnol. 15, 146-149 (1997).
29. + binding site of thrombin. J. Biol. Chem. 270, 22089-22092 (1995).
30. Tsiang, M., et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry 35, 16449-16457 (1996).
31. Le Bonniec, B.F., Guinto, E.R. & Stone, S.R. Identification of thrombin residues that modulate its interactions with antithrombin III and α 1-antitrypsin. Biochemistry 34, 12241-12248 (1995).
32. Izaguirre, G., Zhang, W., Swanson, R., Bedsted, T. & Olson, S.T. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J. Biol. Chem. 278, 51433-51440 (2003).
33. Dementiev, A., Petitou, M., Herbert, J.M. & Gettins, P.G.W. Antithrombin-anhydrothrombin-heparin ternary complex structure reveals the basis of inhibitor specificity. Nat. Struct. Mol. Biol. advance online publication, 15 August 2004 (doi:10.1038/nsmb810).
34. Johnson, D.J. & Huntington, J.A. The influence of hinge region residue Glu381 on antithrombin allostery and metastability. J. Biol. Chem. 279, 4913-4921 (2004).
35. Leslie, A.W.G. Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography Vol. 26 (Daresbury Laboratory, Warrington, UK, 1992).
36. Vagin, A. & Teplyakov, A. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D 56, 1622-1624 (2000).
37. McRee, D.E. A visual protein crystallographic software system for X11/XView. J. Mol. Graph. 10, 44-46 (1992).
38. van Aalten, D.M., et al. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput. Aided Mol. Des. 10, 255-262 (1996).
39. Brunger, A.T., et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921 (1998).
40. Esnouf, R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15, 132 (1997).
41. Merritt, E.A. & Murphy, M.E.P. Raster3d version 2.0: a program for photorealistic molecular graphics. Acta Crystallogr. D 50, 869-873 (1994).
42. Johnson, D.J. & Huntington, J.A. Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 42, 8712-8719 (2003).